Abbrea Capital LLC cut its stake in shares of Pfizer, Inc. (NYSE:PFE) by 2.7% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 53,493 shares of the biopharmaceutical company’s stock after selling 1,467 shares during the period. Abbrea Capital LLC’s holdings in Pfizer were worth $1,797,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. 440 Investment Group LLC lifted its position in Pfizer by 131.7% during the second quarter. 440 Investment Group LLC now owns 34,156 shares of the biopharmaceutical company’s stock valued at $1,147,000 after purchasing an additional 19,414 shares in the last quarter. Grisanti Capital Management LLC lifted its position in Pfizer by 3.7% during the second quarter. Grisanti Capital Management LLC now owns 101,155 shares of the biopharmaceutical company’s stock valued at $3,397,000 after purchasing an additional 3,640 shares in the last quarter. Berkeley Capital Partners LLC lifted its position in Pfizer by 16.7% during the second quarter. Berkeley Capital Partners LLC now owns 36,844 shares of the biopharmaceutical company’s stock valued at $1,238,000 after purchasing an additional 5,262 shares in the last quarter. IFC Holdings Incorporated FL lifted its position in Pfizer by 1.4% during the second quarter. IFC Holdings Incorporated FL now owns 72,447 shares of the biopharmaceutical company’s stock valued at $2,432,000 after purchasing an additional 1,023 shares in the last quarter. Finally, Keystone Financial Planning Inc. lifted its position in Pfizer by 3.2% during the second quarter. Keystone Financial Planning Inc. now owns 187,549 shares of the biopharmaceutical company’s stock valued at $6,300,000 after purchasing an additional 5,741 shares in the last quarter. Institutional investors own 69.36% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Abbrea Capital LLC Reduces Stake in Pfizer, Inc. (PFE)” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/11/14/abbrea-capital-llc-reduces-stake-in-pfizer-inc-pfe.html.

Several equities analysts recently weighed in on PFE shares. Sanford C. Bernstein set a $39.00 target price on Pfizer and gave the company a “buy” rating in a research report on Monday, July 17th. Credit Suisse Group downgraded Pfizer from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $38.00 to $36.00 in a research report on Thursday, July 20th. UBS AG reiterated a “buy” rating and set a $38.00 target price on shares of Pfizer in a research report on Monday, July 31st. Berenberg Bank set a $39.00 target price on Pfizer and gave the company a “neutral” rating in a research report on Tuesday, August 1st. Finally, BMO Capital Markets upgraded Pfizer from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $33.00 to $37.00 in a research report on Wednesday, August 2nd. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $38.48.

In related news, insider Laurie J. Olson sold 8,064 shares of Pfizer stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $32.70, for a total value of $263,692.80. Following the completion of the transaction, the insider now owns 74,506 shares in the company, valued at $2,436,346.20. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Alexander R. Mackenzie sold 14,700 shares of Pfizer stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total value of $518,910.00. Following the completion of the transaction, the insider now owns 117,432 shares of the company’s stock, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 374,621 shares of company stock valued at $12,796,098. 0.06% of the stock is currently owned by company insiders.

Shares of Pfizer, Inc. (NYSE PFE) opened at $35.30 on Tuesday. Pfizer, Inc. has a twelve month low of $30.51 and a twelve month high of $36.78. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. The stock has a market capitalization of $209,697.67, a PE ratio of 14.07, a PEG ratio of 2.49 and a beta of 1.01.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The firm had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. During the same period in the previous year, the firm posted $0.61 earnings per share. The business’s revenue was up .9% compared to the same quarter last year. research analysts anticipate that Pfizer, Inc. will post 2.59 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Friday, November 10th will be given a $0.32 dividend. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 annualized dividend and a yield of 3.63%. Pfizer’s dividend payout ratio is currently 79.01%.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.